Welcome to our dedicated page for APIMEDS PHARMACEUTICALS US SEC filings (Ticker: APUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) provides access to the company’s regulatory disclosures as an Exchange Act registrant with common stock listed on the NYSE American. These filings document key aspects of Apimeds’ evolution as a clinical-stage biopharmaceutical company focused on non-opioid, biologic-based pain therapies and its merger with MindWave Innovations Inc., an institutional Digital Asset Treasury solutions provider.
Among the most informative documents are the company’s current reports on Form 8-K, which describe material events such as the entry into an Agreement and Plan of Merger with MindWave Innovations Inc., Apimeds Merger Sub, Inc., and Lokahi Therapeutics, Inc.; the structure of the merger consideration, including common and preferred stock; and the resulting ownership percentages. Other 8-K filings detail amendments to bylaws to allow shareholder action by written consent, changes to executive employment agreements, and departures or removals of directors, along with the composition of the remaining board.
Filings also address capital structure and financing arrangements, including a Securities Purchase Agreement for senior convertible notes, amendments to that agreement, and a certificate of designation for Series A Convertible Preferred Stock. An amended Form 8-K (8-K/A) explains corrections to the merger agreement and to the number of preferred shares designated, illustrating how Apimeds uses SEC filings to clarify and update previously reported terms.
Investors reviewing APUS filings can trace the company’s initial public offering on the NYSE American, its status as an emerging growth company, and subsequent PIPE financing associated with the MindWave merger, as described across registration statements and current reports. The filings also reference the preparation of an Information Statement under Section 14(c) of the Exchange Act to describe the merger, related stockholder approvals, reverse stock split, and equity incentive plan changes.
On Stock Titan, these SEC documents are supplemented by AI-powered summaries that highlight the main points of lengthy filings, such as 8-Ks and related exhibits. Users can quickly understand how each filing relates to Apimeds’ Apitox development program, its non-opioid pain-management focus, its integration of digital-asset treasury capabilities, and its governance and capital structure decisions, without reading every page in full.
Apimeds Pharmaceuticals US, Inc. received a NYSE American notice of non-compliance because it failed to timely file its Form 10-K for the year ended December 31, 2025. The exchange has given an initial cure period through October 15, 2026, to file the overdue report and any subsequent late filings.
The company expects to submit the Form 10-K by April 30, 2026, but cautions this is not assured. Apimeds’ stock will remain listed under ticker APUS with a “.LF” late-filer tag, while the April 2, 2026 trading halt stays in effect and delisting remains a potential outcome if filings are not brought current.
Apimeds Pharmaceuticals US, Inc. reports a delay in filing its Annual Report on Form 10-K for the year ended December 31, 2025. The company previously filed a Form 12b-25 but now expects it will not meet the additional fifteen-day extension period because its financial statements and audit are still being completed.
Apimeds expects to receive a notice from NYSE American that it is not in compliance with continued listing requirements due to the late 10-K. The company anticipates being given time to submit a plan to regain compliance and is working to finalize the 10-K, targeting a filing date by April 30, 2026, though it cautions there is no assurance this deadline will be met.
Apimeds Pharmaceuticals US, Inc. states that a written Stockholder Consent dated March 20, 2026, which purported to remove several directors and officers, is null and void because it violated binding provisions of the Stockholder Support and Lock-Up Agreement tied to the Merger closed on December 1, 2025. The Company says 6,416,365 shares used in the consent were subject to an irrevocable proxy coupled with an interest and therefore could not be used without the proxy holder's authorization; the Company plans to proceed with actions described in its Schedule 14C information statement.
Apimeds Pharmaceuticals US, Inc. filed an amended report stating that a written Stockholder Consent delivered on March 20, 2026 is null and void. That consent had purported to remove four directors, including Elona Kogan and Dr. Bennett Weintraub, and to remove Dr. Vin Menon as CEO and Erick Frim as CFO.
The company explains that the consent used 6,416,365 shares of common stock that were subject to an irrevocable proxy granted to the company under a Stockholder Support and Lock-Up Agreement related to its merger with MindWave Innovations Inc. Because the proxy holder did not authorize their use and the consent also conflicted with waiver and anti‑frustration covenants in that agreement, the company states the consent and related bylaw amendments are of no force or effect. As a result, Apimeds plans to proceed with actions described in its Schedule 14C information statement previously mailed to stockholders.
Apimeds Pharmaceuticals US, Inc. notified the SEC that it cannot file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 on time and expects to file within the fifteen‑day grace period provided by Rule 12b-25.
The Company says it needs additional time to complete its year-end financial statements and for its independent auditor to finish the review and audit.
Apimeds Pharmaceuticals US, Inc. is implementing a 1-for-10 reverse stock split of its issued and outstanding common stock. Stockholders holding a majority of the voting power approved the action by written consent on December 1, 2025.
The company plans to file a charter amendment in Delaware on or about March 25, 2026, and has set 12:01 a.m. Eastern Time on March 26, 2026 as the effective time. Apimeds expects its common stock to begin trading on a split-adjusted basis on the NYSE American under the symbol APUS on March 26, 2026, with a new CUSIP of 03771D201.